Today: Today, 3,627 Shares of Bristol-Myers Squibb Co. (BMY) are sold by Bremer Trust National Association

Today, 3,627 Shares of Bristol-Myers Squibb Co. (BMY) are sold by Bremer Trust National Association

Bremer Trust National Association decreased its position in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 17.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 17,519 shares of the biopharmaceutical company’s stock after selling 3,627 shares during the period. Bremer Trust National Association’s holdings in Bristol-Myers Squibb were worth $944,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in BMY. WESPAC Advisors SoCal LLC boosted its position in shares of Bristol-Myers Squibb by 5.1% in the second quarter. WESPAC Advisors SoCal LLC now owns 1,538 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 75 shares during the period. Acropolis Investment Management LLC boosted its position in shares of Bristol-Myers Squibb by 21.3% in the third quarter. Acropolis Investment Management LLC now owns 2,815 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 495 shares during the period. Jolley Asset Management LLC boosted its position in shares of Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 80 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth $163,000. Finally, Solaris Asset Management LLC boosted its position in shares of Bristol-Myers Squibb by 3.5% in the second quarter. Solaris Asset Management LLC now owns 2,244 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 75 shares during the period. 71.28% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.41% during midday trading on Friday, reaching $56.98. 6,228,571 shares of the company’s stock were exchanged. Bristol-Myers Squibb Co. has a 1-year low of $49.03 and a 1-year high of $77.12. The company has a market capitalization of $95.23 billion, a PE ratio of 28.50 and a beta of 0.90. The firm has a 50-day moving average of $52.69 and a 200-day moving average of $63.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.65 by $0.12. The firm earned $4.83 billion during the quarter, compared to analysts’ expectations of $4.76 billion. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. Bristol-Myers Squibb’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period last year, the business earned $0.39 earnings per share. Equities analysts expect that Bristol-Myers Squibb Co. will post $2.85 earnings per share for the current fiscal year.

A number of research analysts have recently commented on BMY shares. Leerink Swann reissued an “outperform” rating and set a $69.00 target price on shares of Bristol-Myers Squibb in a research report on Sunday, October 9th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Thursday, October 20th. Morgan Stanley cut shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $63.00 target price on the stock. in a research report on Friday, August 5th. Jefferies Group reissued a “hold” rating and set a $57.00 target price (down from $69.00) on shares of Bristol-Myers Squibb in a research report on Monday, September 12th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating on shares of Bristol-Myers Squibb in a research report on Monday, September 12th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $67.51.

In related news, Director Lamberto Andreotti sold 21,600 shares of the firm’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $56.87, for a total value of $1,228,392.00. Following the completion of the transaction, the director now directly owns 334,499 shares of the company’s stock, valued at $19,022,958.13. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.24% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Related posts

Leave a Comment